Clovis Oncology Inc (CLVS) 2021年年度报告「NASDAQ」.pdf

1、Table of ContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-KANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934.For the fiscal year ended December 31,2021.TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT

2、OF 1934.For the transition period from to .Commission file number:001-35347Clovis Oncology,Inc.(Exact name of Registrant as specified in its charter)Delaware 90-0475355(State or other jurisdiction ofincorporation or organization)(I.R.S.EmployerIdentification No.)5500 Flatiron Parkway,Suite 100Boulde

3、r,Colorado80301(Address of principal executive offices)(Zip Code)(303)625-5000(Registrants telephone number,including area code)Not Applicable(Former name,former address and former fiscal year,if changed since last report)Securities registered pursuant to Section 12(b)of the ActTitle of Each ClassTr

4、ading Symbol(s)Name of each exchange on which registeredCommon Stock par Value$0.001 per shareCLVSThe NASDAQ Global Select MarketIndicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No Indicate by check mark if the registrant is no

5、t required to file reports pursuant to Section 13 or Section 15(d)of the Act.Yes No Indicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934during the preceding 12 months(or for such shorter period that th

6、e registrant was required to file such reports),and(2)has been subject to such filingrequirements for the past 90 days.Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T(232.405)